Impax Asset Management Group plc Has $5.93 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Impax Asset Management Group plc increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,643 shares of the biopharmaceutical company’s stock after buying an additional 248 shares during the period. Impax Asset Management Group plc’s holdings in Regeneron Pharmaceuticals were worth $5,932,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. International Assets Investment Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares during the last quarter. Capital International Investors lifted its position in Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after acquiring an additional 213,038 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Regeneron Pharmaceuticals by 25.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after purchasing an additional 184,561 shares during the last quarter. Swedbank AB bought a new stake in Regeneron Pharmaceuticals during the first quarter worth about $129,257,000. Finally, Epoch Investment Partners Inc. bought a new position in Regeneron Pharmaceuticals in the 1st quarter valued at about $99,667,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

REGN has been the topic of several analyst reports. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Friday. They set an “outperform” rating and a $1,150.00 price target on the stock. Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Guggenheim upped their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Royal Bank of Canada lowered their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Finally, Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,099.55.

Insider Activity

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $756.81 on Friday. The firm has a market cap of $83.17 billion, a PE ratio of 18.73, a price-to-earnings-growth ratio of 3.04 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 52-week low of $753.69 and a 52-week high of $1,211.20. The business’s 50 day moving average price is $992.70 and its two-hundred day moving average price is $1,033.92. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.